150 related articles for article (PubMed ID: 1978512)
1. The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys.
Parent A; Lavoie B; Smith Y; Bédard P
Adv Neurol; 1990; 53():111-6. PubMed ID: 1978512
[TBL] [Abstract][Full Text] [Related]
2. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
[No Abstract] [Full Text] [Related]
3. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients.
Jan C; François C; Tandé D; Yelnik J; Tremblay L; Agid Y; Hirsch E
Eur J Neurosci; 2000 Dec; 12(12):4525-35. PubMed ID: 11122363
[TBL] [Abstract][Full Text] [Related]
4. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
Nagatsu T
Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515
[No Abstract] [Full Text] [Related]
5. Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
Schneider JS; Dacko S
Brain Res; 1991 Aug; 556(2):292-6. PubMed ID: 1682010
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey.
Smith Y; Lavoie B; Dumas J; Parent A
Brain Res; 1989 Mar; 482(2):381-6. PubMed ID: 2565144
[TBL] [Abstract][Full Text] [Related]
7. MPTP-Induced pallidal lesions in rhesus monkeys.
Zhang Z; Zhang M; Ai Y; Avison C; Gash DM
Exp Neurol; 1999 Jan; 155(1):140-9. PubMed ID: 9918713
[TBL] [Abstract][Full Text] [Related]
8. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
9. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Belzunegui S; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neuropathol Exp Neurol; 2009 Jan; 68(1):26-36. PubMed ID: 19104449
[TBL] [Abstract][Full Text] [Related]
10. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
11. The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys.
Parent A; Lavoie B
Adv Neurol; 1993; 60():25-33. PubMed ID: 7678366
[TBL] [Abstract][Full Text] [Related]
12. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
13. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
Bian GL; Wei LC; Shi M; Wang YQ; Cao R; Chen LW
Brain Res; 2007 May; 1150():55-61. PubMed ID: 17397812
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C
Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469
[TBL] [Abstract][Full Text] [Related]
15. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Rolland AS; Tandé D; Herrero MT; Luquin MR; Vazquez-Claverie M; Karachi C; Hirsch EC; François C
J Neurochem; 2009 Aug; 110(4):1321-9. PubMed ID: 19527435
[TBL] [Abstract][Full Text] [Related]
18. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
Schneider JS; Yuwiler A; Markham CH
Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of MPTP to marmosets.
Albanese A; Altavista MC; Gozzo S; Rossi P; Colosimo C; Bentivoglio AR; Perretta G; Elia M; Monaco V; Macchi G
Adv Neurol; 1990; 53():239-44. PubMed ID: 1978517
[No Abstract] [Full Text] [Related]
20. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
